The foreign trade surplus of my country's pharmaceutical trade in the first half of the year was US$7.051 billion

In the first half of the year, the import and export volume of China's pharmaceutical trade reached 43.237 billion US dollars, up 10.28% year on year Among them, exports reached US $25.144 billion, an increase of 7.11%, imports reached US $18.093 billion, an increase of 15.01%, and foreign trade surplus reached US $7.051 billion This was disclosed at a forum organized by China Chamber of Commerce for import and export of medical and health products In the first half of the year, the global economic growth momentum was insufficient, and the international market demand was not fundamentally improved, resulting in the decline of international pharmaceutical trade In response to the adverse changes in the situation, China Chamber of Commerce for the import and export of medical and health care products has guided and coordinated the industry and enterprises to actively respond, such as coordinating the EU directive 62 and the classification of customs codes, organizing VC anti monopoly response, organizing CPHI exhibition and other large-scale pharmaceutical exhibitions, and held a series of key international market trade promotion activities, alleviating the difficulties of import and export enterprises, and enhancing the confidence of enterprises 。 In the first half of this year, the main characteristics of foreign trade in medicine are as follows: 1 The developed market is in a continuous downturn, and the demand in emerging markets is strong 1 The export growth of China's pharmaceutical products to developed markets such as Europe, the United States and Japan was 3.27%, accounting for 55.26% of the export market, down 2 percentage points from the same period last year 2 The emerging pharmaceutical market is full of vitality The export of Chinese pharmaceutical products to the emerging market increased by 11.37%, accounting for 24.54% of the export, an increase of 1 percentage point over last year 2 The export structure has been further optimized, the tension of export transformation has increased, medical devices and characteristic APIs have increased substantially, and the export of Western medicine preparations has grown strongly 1 The export of medical devices grew steadily In the first half of the year, China's medical device export reached 9.011 billion US dollars, a year-on-year increase of 10.87%, accounting for 1.2 percentage points of China's medical device export, to 35.84% 2 The export volume of characteristic APIs will increase rapidly, and the export of preparations will usher in a period of rapid growth According to incomplete statistics, in the first half of the year, China's export of characteristic APIs reached US $1.067 billion, an increase of 11.23% year on year, accounting for more than 80% of its exports to major markets such as India, the United States, the European Union, Japan and South Korea In the first half of the year, the export of Western pharmaceutical preparations reached US $1.357 billion, up 7.93% year on year It is expected that the export of pharmaceutical preparations in the second half of the year will usher in a new round of outbreak Third, the cost advantage has declined, weakening the market competitiveness of medical dressings, disposable consumables and other products In the first half of the year, China's medical dressing export ended a long-term double-digit high growth, only a slight increase of 1.01% year-on-year At present, based on the analysis of basic data, the overall medical dressing industry in China is characterized by small market scale, low industry concentration, product homogeneity and low added value With the fierce market competition, the competition of enterprises mainly focuses on the price competition, and the industry is in the stage of low level competition The domestic cotton price is high, and the international competition is intense According to GTA data, Mexico, Brazil, Thailand and India have significantly surpassed China in the export of medical dressings, reaching 11.06%, 7.25%, 21.2% and 66.94% respectively The markets of the United States and the European Union have been occupied and competition has intensified The growth rate of disposable consumables exports also fell sharply, with an increase of only 8.42% in the first half of the year, compared with 30.53% in the same period last year 4 Plant extracts and traditional Chinese medicine have boosted the export of traditional Chinese medicine In the first half of the year, the export of traditional Chinese medicine rose rapidly, with the export amount of US $1491 million, an increase of 22.49% year on year, showing a trend of volume and price rising, and the increase came from the substantial increase in the export of extracts and traditional Chinese medicine Among them, the domestic price of traditional Chinese medicine materials has been rising continuously in recent two years International customers, especially Japanese, Korean and ASEAN merchants, reduced their purchase volume last year, which led to the decrease of inventory in the first half of this year, increased the purchase volume, and stimulated the further price rise In the first half of this year, the export price and volume of traditional Chinese medicine increased by 30.44% and 8.24% respectively compared with the same period last year It is expected that this favorable situation will continue in the second half of this year The export price of plant extracts was affected by the rising price of raw materials of traditional Chinese medicine In the first half of the year, the export price was 694 million US dollars, up 17.16% year on year At present, due to the weakening of the export of traditional Chinese patent medicines, the international market will increase the demand for plant extracts, and the demand for plant extracts in the United States, India, Germany and other international markets will continue to grow Many domestic mainstream pharmaceutical enterprises are optimistic about this situation and are entering or preparing to enter this field The export of Shaanxi Jiahe plant chemical industry, Ganzhou Julong high tech and other enterprises has doubled in explosive growth, which is expected to effectively promote the further growth of the export of traditional Chinese medicine products V the pharmaceutical import has entered a moderate growth period After the blowout growth in 2011, the growth rate of pharmaceutical import has entered a relatively stable growth track in the past two years In the first half of the year, the import of medical and health care products reached US $18.093 billion, up 15.01% year on year Among them, the import of API was driven by foreign investment, and some characteristic API procurement was transferred to China The growth rate continued to slow down, with an increase rate of 4.66%, a proportion of 20.76%, a decrease of 2.1% The import of Western medicine accounted for 29.28% of the total, up 10.99% year on year; the import of diagnosis and treatment equipment was 4.88billion US dollars, up 11.42% year on year It is worth noting that in the first half of this year, the biomedical import of Roche, Abbott and other multinational pharmaceutical companies reached US $1.648 billion, an increase of 36.50% year on year Therefore, it is judged that multinational pharmaceutical companies are increasing their investment in China's biomedical and diagnostic reagents Outlook for the second half of the year In the second half of the year, the International Monetary Fund recently predicted that the economic growth of developed countries is expected to increase in the second half of the year, and that of developing countries is expected to be better than that of the previous year However, the deep adjustment caused by the international financial crisis is still continuing, and the world economy will still present a weak recovery situation, and the potential risks cannot be underestimated In the medium and long term, China's position as a global manufacturing factory will not change China has perfect industrial supporting and processing capacity, and the comparative advantage of export enterprises still exists Under this expectation, China's pharmaceutical foreign trade is expected to enter a relatively long and complex period, and the unstable and uncertain factors will increase The export of APIs to the EU will survive the most difficult period in the third quarter, and the growth of characteristic APIs, western medicine preparations, medical equipment, etc will continue to be rapid The market demand in Europe and the United States is still difficult to change significantly, and the share of emerging markets is expected to continue to expand It is expected that the pharmaceutical import and export will achieve a small growth year on year.